Qu Biologics Inc., a biotechnology firm currently developing Site Specific Immunomodulators (SSIs) to restore regular immune function in a specific targeted diseased organ, recently announced that the United States Patent and Trademark Office issued a U.S. Patent to the company for the utilization of immunotherapies that are collected from components of E. coli with the purpose of treating Crohn’s disease.
The patent was issued on March 17, 2015 and it claims the usage of E. coli components such as SSIs to boost the immune response and provide treatment for Crohn’s disease. This recent patent is based on Qu Biologics’ patent portfolio that includes SSI treatment of multiple inflammatory disorders and cancers.
Hal Gunn, who is the Qu Biologics’ Chief Executive Officer said in a press release: “We are very pleased to have been granted this important U.S. patent that covers our novel Crohn’s treatment in clinical use in our randomized, placebo-controlled clinical trial. Our SSIs aim to address the underlying immunological causes of many chronic inflammatory diseases, representing a novel treatment approach that restores the body’s own immune response. We will continue to further strengthen our patent position as we advance our clinical trials in inflammatory bowel disease.”
The Site Specific Immunomodulators (SSIs) from Qu Biologics are obtained from components of bacteria and are designed to treat cancer and other immune-related diseases like ulcerative colitis and Crohn’s disease by stimulating the body’s immune system. Qu Biologics has advanced multiple SSIs, each of which targets a specific organ/tissue.
Qu Biologics’ Site Specific Immunomodulators (SSIs) are derived from components of bacteria and are designed to stimulate the body’s immune system to treat cancer and other immune-related diseases, such as Crohn’s disease and ulcerative colitis. Qu Biologics has advanced several SSIs so that specific tissues or organs are target.
In other recent Qu Biologics news, the company recently announced that a Data Safety Monitoring Committee (DSMC) completed a review of one of their pipeline product’s safety data from a 30-patient (50% enrollment) clinical trial. The product, QBECO SSI, is indicated for the treatment of Crohn’s disease and has received clearance to proceed with further clinical research, which the committee will continue to monitor.